Fledgling Pharma FerGene Makes Quick Debut With Gene Therapy Candidate

07 Dec 2019

• By Leah Samuel

FerGene bladder cancer therapy achieved a complete response in more than half of patients in its pivotal trial. The joint venture now looks to commercialization and potential expansion of indications.

Bladder cancer medical concept as an anatomical organ symbol with microscopic malignant cells spreading in the human body as a health care 3D illustration.

FerGene debuted less than a month ago, formed to support the launch of the bladder cancer gene therapy nadofaragene firadenovec, and on 5 December presented pivotal data showing an early and durable response in its Phase III trial.

The news gives Ferring Pharmaceuticals AS, FerGene’s parent company, a fast start for its first move into gene therapy....